表紙
市場調査レポート

心臓発作:パイプライン分析

Heart Attack - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 288832
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
心臓発作:パイプライン分析 Heart Attack - Pipeline Review, H2 2015
出版日: 2015年09月09日 ページ情報: 英文 46 Pages
概要

心臓発作は、心筋が損傷するか死に至るまでに十分な長い時間、心臓の一部の血流が閉鎖された場合に発生します。症状には、不安、咳、吐き気または嘔吐、動悸および息切れがあります。治療には、手術、不整脈治療薬、ACE阻害剤および抗血小板薬などが含まれます。

当レポートでは、世界における心臓発作治療薬のパイプラインについて取り上げ、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

  • 分析範囲

心臓発作の概要

治療薬の開発

  • 心臓発作向けパイプライン製品:概要
  • 心臓発作向けパイプライン製品:比較分析

心臓発作:開発中の治療薬:企業別

心臓発作:開発中の治療薬:大学・研究機関別

心臓発作:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

心臓発作:開発中の製品:企業別

心臓発作:開発中の製品:大学・研究機関別

心臓発作:治療薬開発に従事している企業

  • APT Therapeutics, Inc.
  • Lacer, S.A.
  • Lanthio Pharma B.V.

心臓発作:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AB-002
  • APT-102
  • 心血管疾患治療用αミオシン阻害剤
  • LA-8045
  • LWnt-3a
  • Lysimab
  • NVX-308
  • 糖尿病および心不全治療用アぺリン受容体刺激ペプチド
  • 再かん流傷害および心臓発作治療用小分子
  • 心血管疾患治療用PDE5阻害剤
  • TF-0023

パイプライン製品の最新アップデート

休止状態のプロジェクト

製品開発のマイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7132IDB

Summary

Global Markets Direct's, 'Heart Attack - Pipeline Review, H2 2015', provides an overview of the Heart Attack's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Heart Attack, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Heart Attack and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Heart Attack
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Heart Attack and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Heart Attack products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Heart Attack pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Heart Attack
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Heart Attack pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Heart Attack Overview
  • Therapeutics Development
    • Pipeline Products for Heart Attack - Overview
    • Pipeline Products for Heart Attack - Comparative Analysis
  • Heart Attack - Therapeutics under Development by Companies
  • Heart Attack - Therapeutics under Investigation by Universities/Institutes
  • Heart Attack - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Heart Attack - Products under Development by Companies
  • Heart Attack - Products under Investigation by Universities/Institutes
  • Heart Attack - Companies Involved in Therapeutics Development
    • APT Therapeutics, Inc.
    • Lacer, S.A.
    • Lanthio Pharma B.V.
  • Heart Attack - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APT-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LA-8045 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LWnt-3a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lysimab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVX-308 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Reperfusion Injury and Heart Attack - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TF-0023 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Heart Attack - Recent Pipeline Updates
  • Heart Attack - Dormant Projects
  • Heart Attack - Product Development Milestones
    • Featured News & Press Releases
      • Oct 02, 2014: APT Therapeutics' Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Heart Attack, H2 2015
  • Number of Products under Development for Heart Attack - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Heart Attack - Pipeline by APT Therapeutics, Inc., H2 2015
  • Heart Attack - Pipeline by Lacer, S.A., H2 2015
  • Heart Attack - Pipeline by Lanthio Pharma B.V., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Heart Attack Therapeutics - Recent Pipeline Updates, H2 2015
  • Heart Attack - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Heart Attack, H2 2015
  • Number of Products under Development for Heart Attack - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top